Pharmaceuticals

Primary Biliary Cholangitis Therapeutics Global Forecast: Market to Scale Up to $1.85 Billion by 2030 at 12.9% CAGR

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the primary biliary cholangitis therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Primary Biliary Cholangitis Therapeutics Market covering 2026–2035?

The market for primary biliary cholangitis therapeutics has experienced rapid expansion in recent years. This market is projected to expand from $1.01 billion in 2025 to reach $1.14 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. Historically, this growth can be ascribed to several factors, including the scarcity of treatment alternatives for PBC, an increasing incidence of autoimmune liver conditions, rising awareness initiatives concerning liver diseases, the dependence on ursodeoxycholic acid as a sole therapy, and the development of hospital facilities dedicated to liver disease management.

The market for primary biliary cholangitis therapeutics is projected to experience substantial expansion in the coming years. This market is anticipated to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.9%. Several factors are contributing to this projected growth, including advancements in obeticholic acid and combination treatments, an increase in investigational medications and pipeline prospects, wider acceptance of receptor agonists and modulators, heightened patient understanding and proactive diagnostic efforts, and the expansion of distribution channels through online and retail pharmacies. Key trends expected during this period involve the growing use of ursodeoxycholic acid and obeticholic acid treatments, the development of more combination therapies and pipeline drugs, a greater emphasis on early detection and disease management, the broadening of hospital and retail pharmacy distribution channels, and increased awareness of autoimmune liver conditions alongside patient education efforts.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Primary Biliary Cholangitis Therapeutics Market?

The expanding occurrence of liver ailments is projected to drive the primary biliary cholangitis therapeutics market’s expansion in the future. Liver ailments encompass various conditions that hinder the liver’s normal operation, frequently resulting in inflammation, scarring, or ultimate liver failure. The rising incidence of liver conditions is attributable to increased alcohol consumption, given that excessive alcohol consumption harms liver cells, causing inflammation and persistent liver issues. Primary biliary cholangitis therapeutics assist in managing liver ailments by addressing bile duct inflammation, decelerating the advancement of the disease, and safeguarding liver functionality. These treatments enhance patient results by alleviating symptoms, improving the quality of life, and postponing the necessity for liver transplantation. For example, in September 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported that chronic liver disease and cirrhosis led to 52,222 deaths in the United States in 2023, ranking as the ninth leading cause of death. Consequently, the rising occurrence of liver diseases is fueling the growth of the primary biliary cholangitis therapeutics market.

What Leading Segments Are Studied In The Primary Biliary Cholangitis Therapeutics Market?

The primary biliary cholangitis therapeutics market covered in this report is segmented –

1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs

2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action

3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

4) By Use: Human, Veterinary

Subsegments:

1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid

2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid

3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates

Which Trends Are Influencing The Performance And Direction Of The Primary Biliary Cholangitis Therapeutics Market?

Major companies operating in the primary biliary cholangitis therapeutics market are concentrating on developing advanced products and securing approvals, including for peroxisome proliferator-activated receptor agonists, with the aim of enhancing bile acid metabolism and impeding disease progression in affected individuals. Peroxisome proliferator-activated receptor (PPAR) agonists function as medications that activate PPAR proteins, known for regulating genes crucial to metabolism, inflammation, and energy balance. As an illustration, in August 2024, Gilead Sciences Inc., a pharmaceutical firm based in the US, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for its drug Livdelzi (seladelpar) for addressing primary biliary cholangitis (PBC) in adults who have shown an insufficient response to or intolerance of ursodeoxycholic acid (UDCA). This medication is an oral, selective PPARd agonist, operating by activating the PPARd receptor to modulate genes responsible for decreasing liver inflammation, enhancing bile acid metabolism, and slowing the advancement of primary biliary cholangitis (PBC).

Which Key Players Are Driving Competition In The Primary Biliary Cholangitis Therapeutics Market?

Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-therapeutics-global-market-report

Which Region Is Projected To Lead The Primary Biliary Cholangitis Therapeutics Market During The Forecast Period?

North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Biliary Cholangitis Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25887&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Therapeutics Market 2026, By The Business Research Company

Primary Biliary Cholangitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Liver Diseases Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795